Oruka Stock Surges on Positive Psoriasis Trial Data

Positive Trial Data Boosts Oruka Therapeutics Stock

Oruka Therapeutics Inc. NASDAQ:ORKA shares surged 45 percent following the announcement of positive Week 16 data from its EVERLAST-A Phase 2a trial for ORKA-001, a treatment for moderate-to-severe plaque psoriasis.

Trial Efficacy and Safety Overview

The trial successfully met its primary endpoint, with 63.5 percent of participants treated with ORKA-001 achieving complete skin clearance, defined as PASI 100. Key secondary endpoints were also strong, with 83 percent of patients reaching PASI 90. The drug demonstrated a favorable safety profile consistent with the IL-23p19 class, with no serious treatment-emergent adverse events reported in the treatment group.

Market Impact and Future Outlook

The strong clinical results significantly bolstered investor confidence, positioning ORKA-001 as a promising candidate in the competitive psoriasis treatment market. The company noted that pharmacokinetic data supports the potential for a once-yearly dosing schedule, with longer-term trial data anticipated in the second half of 2026.

Summary

The positive Phase 2a data represents a key milestone for Oruka Therapeutics, reducing clinical risk and highlighting the drug's potential efficacy. Market attention will now turn to the long-term data and subsequent steps in the regulatory process.

FAQ

Q: What was the main result from the ORKA-001 trial?
A: The trial's primary endpoint was met, with 63.5 percent of patients achieving complete skin clearance at Week 16.

Q: How did Oruka Therapeutics stock react to the news?
A: The company's stock, trading under the ticker ORKA, rose by 45 percent after the data was released.

Source: Investing.com